Nuformix Plc Financials
NFX.XLON
All currency values in £ millions unless otherwise noted
| Income Statement | SEP 2025 | SEP 2024 | MAR 2022 | MAR 2021 |
|---|---|---|---|---|
| Revenues | ||||
| Revenue | £0 | £0 | £0 | £0 |
| Cost of Revenue | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| Total Operating Expenses | £1 | £1 | £1 | £2 |
| Operating Income | -£1 | -£1 | -£1 | -£1 |
| Non-Operating | ||||
| Net Interest Expense | – | – | £0 | -£0 |
| Income Tax Expense | -£0 | -£0 | -£0 | -£0 |
| Net Income | ||||
| Net Income | -£1 | -£4 | -£1 | -£1 |
| Per Share Data | ||||
| Revenue Per Share | £0.00 | £0.00 | £0.00 | £0.00 |
| EPS (Basic) | -£0.00 | -£0.00 | -£0.00 | -£0.00 |
| EPS (Diluted) | -£0.00 | -£0.00 | -£0.00 | -£0.00 |
| Shares Outstanding | 1.66B | 786.9M | 598.4M | 580.6M |
Nuformix (NFX.XLON) financials: revenue, profit and margins
Nuformix (NFX.XLON) generated about £0.00 in revenue and -£652,586.00 in net income over the trailing twelve months, growing at roughly -74.4% a year. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is Nuformix's (NFX.XLON) revenue?+
Nuformix generated about £0.00 in revenue over the trailing twelve months. Revenue has grown at roughly -74.4% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Nuformix profitable?+
Nuformix reported about -£652,586.00 in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
How fast is Nuformix growing?+
Nuformix's revenue has compounded at roughly -74.4% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside NFX.XLON's margins and free cash flow. This is analysis from company filings, not investment advice.
Peers
Biotechnology · Pick stocks to compare with NFX.XLON
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing NFX.XLON
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.